Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00196664
Status:
COMPLETED
Last Update Posted:
2009-05-13
First Post:
2005-09-13
Brief Title:
Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin
Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Organization:
French National Agency for Research on AIDS and Viral Hepatitis
Study Overview
Official Title:
Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin Multicentric Double-Blinded Randomized Study ANRS HC18 Paropeg
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Depression is a common side effect of interferon in the treatment of chronic hepatitis C The aim of this study is to assess the efficacy and safety of paroxetine an antidepressant agent in the prevention of depression induced by PEG-interferon given for the treatment of chronic hepatitis C
Detailed Description:
The aim of this study is to assess the efficacy and safety of paroxetine an antidepressant agent in the prevention of depression induced by PEG-interferon given for the treatment of chronic hepatitis C This is a comparative study including two groups of patients randomly allocated one with paroxetine and the other with the placebo The rate of depression will be compared between the 2 groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ANRS HC18 PAROPEG | None | None | None |